CSL share price lower despite UK Government deal

CSL has got the UK's back if there's another pandemic.

| More on:
A smiling young woman sits on a bridge in London checking her online shopping, indicating share price movement for ASX BNPL shares overseas.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Limited (ASX: CSL) share price is falling on Wednesday.

In morning trade, the biotherapeutics giant's shares are down 1.5% to $251.94.

Why is the CSL share price falling?

Investors have been selling the company's shares today after broad market weakness offset the release of some potentially positive news.

At the time of writing, the ASX 200 index is down 0.25% following a very poor night of trade on Wall Street.

What did CSL announce?

Overnight, CSL announced a deal between its CSL Seqirus business and the UK government.

According to the release, CSL Seqirus will develop and supply pandemic influenza vaccines in the event of an influenza pandemic.

Under the terms of the agreement, should an influenza pandemic be declared, the UK government would have the option to purchase more than 100 million doses of pandemic vaccines from the CSL Seqirus manufacturing plant in Liverpool in a rapid timeframe.

CSL Seqirus' global executive director for pandemic, Marc Lacey, commented:

CSL Seqirus is a global leader in pandemic influenza preparedness, and we're pleased the UK government will continue to partner with us in preparing to provide protection against the potential of a flu pandemic. This agreement will help to ensure the UK maintains robust preparedness and rapid response capabilities for this potential future threat.

Lorna Meldrum from CSL Seqirus added:

CSL Seqirus has been an active and reliable partner to the UK across pandemic influenza vaccines for many years. We are proud to play a continued part in ensuring ever higher levels of influenza preparedness in the UK and globally.

No financial terms were disclosed for the deal.

While this is good news for the company, let's hope that CSL Seqirus won't be needed!

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Guess which ASX All Ords stock just crashed 23% on earnings miss

Investors are sending the ASX All Ords stock tumbling on Friday. But why?

Read more »

Lab worker puts hands in the air and dances around.
Healthcare Shares

Guess which ASX 300 stock just jumped 12% on FDA approval

Investors are piling into the ASX 300 stock following big US news.

Read more »

A bearded man holds both arms up diagonally and points with his index fingers to the sky with a thrilled look on his face over these rising Tassal share price
Healthcare Shares

Broker says Telix shares could surge 80% higher after selloff

Let's see what Bell Potter has to say about this beaten down healthcare share.

Read more »

A doctor looks unsure.
Dividend Investing

Down 11% in a year, are CSL shares now a good income buy?

CSL shares have faced headwinds from potential US pharmaceutical tariffs.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

What does Macquarie think Resmed shares are worth after its result?

Resmed's share price is gaining momentum.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward representing the ASX tech share sell-off today
Share Fallers

Why did the Telix share price just plunge 18%?

ASX investors are punishing Telix shares today. But why?

Read more »

A man pulls a shocked expression with mouth wide open as he holds up his laptop.
Healthcare Shares

ResMed share price is on watch for all-time highs

Powered by rising margins, global growth, and confidence from management, this sleep tech stock is turning heads again.

Read more »

Medical workers examine an xray or scan in a hospital laboratory.
Healthcare Shares

Why this $7 billion ASX 200 healthcare share is now trading at a discount

With revenue surging, a leading expert believes the ASX 200 healthcare stock has been oversold.

Read more »